FindTrial
Sign In

blood test to detect the presence or absence of cancer

A blood test to determine the probability of developing cancer and/ or its stage, by analysing the expression profile of molecular immuno-markers in healthy and cancer patients (with histologically or cytologically proven malignancy-solid tumors or haematological malignancy) - BTDPC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017166
Enrollment
1000
Registered
2019-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: HrC Diagnostic Blood test: To determine the expression and mutation profile of molecular immuno-marker Control Intervention1: Circulating Tumour Cells and circulating Tumour DNA: To de

Sponsors

Epigeneres Biotech Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Have any type of histologically or cytologically proven (solid tumors or haematological ) cancer which will assist in meeting the Primary objective of this study (Cancer group) (OR) ï?· Individuals who are NOT a known case of any malignancy( Non-Cancer group) ï?· Are aged 18 years or older. ï?· Are willing to consent to storage of specimens for future research. ï?· Are willing to comply with study procedures and follow-ups ï?· Subjects enrolled will be able to provide informed consent for themselves.

Exclusion criteria

Exclusion criteria: Are incarcerated. ï?· Are unwilling or unable to comply with prescribed therapy. ï?· Subjects that lack the capacity to provide informed consent autonomously are to be excluded. ï?· Pregnant or lactating women. ï?· Subjects who have participated in any clinical trial in the past 1 month. ï?· Any subjects found to have entered into the study in violation of this protocol or if the subject is uncooperative during the study ï?· Any other condition that in the opinion of the investigator that does not justify the subjectâ??s participation in the trial.

Design outcomes

Primary

MeasureTime frame
The expression profile of the molecular immuno- markers will help in analysing the probability of manifestation of cancer, before any clinical symptoms begin to appear in healthy individuals. The expression profile of the molecular immuno-markers in cancer patients will help in determining the efficacy of the ongoing treatment and for cancer survivors it will aid in determining the risk of relapse of the disease.Timepoint: 30 days—

Secondary

MeasureTime frame
To follow up with pre-cancer/ high-risk individuals and selected cancer individuals with telephonic visits every 3 months and conduct blood test at every six monthsTimepoint: five years—

Countries

India

Contacts

Public ContactDr Anantbhushan Ranade

Sanjeevan Hospital

draaranade@gmail.com8380001586

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026